Yanliang Zhang

Title: **Innovator Spotlight: Yanliang Zhang**

Introduction

Yanliang Zhang, located in San Diego, CA, is a prominent inventor with a remarkable portfolio that includes seven patents. His contributions to the field of biotechnology focus on innovative therapies that harness the power of antigen receptors.

Latest Patents

Zhang's latest patents demonstrate his cutting-edge work in immunotherapy. One of his significant inventions is the **Dimeric Antigen Receptors**, which are constructs that integrate a heavy chain binding region and a light chain binding region within two distinct polypeptide chains. These dimeric antigen receptors exhibit antibody-like properties that allow for specific binding to target antigens, paving the way for directed cell therapy.

Another noteworthy patent involves **CD-38 Directed Chimeric Antigen Receptor Constructs**. This patent discloses fully human antibodies that specifically bind to CD38, along with their binding fragments, derivatives, and related nucleic acids. This innovation offers methods for creating such antibodies and utilizing them in treating diseases, showcasing the therapeutic potential of Zhang's research.

Career Highlights

Zhang has significantly impacted the industry through his work at various reputable companies, including Sorrento Therapeutics, Inc. and Vivasor, Inc. His expertise in developing novel therapeutic solutions has placed him at the forefront of immunological research.

Collaborations

Throughout his career, Zhang has collaborated with esteemed colleagues such as Heyue Zhou and Edwige Gros. These partnerships contribute to the interdisciplinary approach needed in advancing research and development in biomedicine.

Conclusion

Yanliang Zhang's innovative mind and dedication to harnessing the power of immunotherapy are evident through his patents and collaborations. His work continues to influence the field of biotechnology, making significant strides towards effective treatments for various diseases.